SCHEMBL5563267

SCHEMBL5563267

Cc1cc(-c2cccc(C(=O)CC(=O)Nc3cc(C(F)(F)F)c(C)cc3NC(=O)OC(C)(C)C)c2)cc(C2CC2)n1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.37
ACACA Q13085 2/20 0.37
AAK1 Q2M2I8 3/20 0.36
POLB P06746 1/20 0.35
TGFBR1 P36897 1/20 0.34
RAF1 P04049 1/20 0.34
MDM2 Q00987 1/20 0.34
HDAC3 O15379 2/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
CDK8 P49336 1/20 0.33
CYP3A4 P08684 1/20 0.33
GRM2 Q14416 1/20 0.33
GRM3 Q14832 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5562826 0.91 AAK1 (0.41) ACACBACACAAAK1POLBTGFBR1
SCHEMBL5562837 0.91 TGFBR1 (0.39) ACACBACACAAAK1POLBTGFBR1
SCHEMBL5562983 0.90 AAK1 (0.39) ACACBACACAAAK1TGFBR1GRM2
SCHEMBL27597142 0.90 POLB (0.41) POLBRAF1CDK8CYP3A4GRM2
SCHEMBL5556303 0.88 AAK1 (0.36) ACACBACACAAAK1POLBLIPG
SCHEMBL5563356 0.88 IDO1 (0.38) ACACBACACAAAK1POLBTGFBR1
SCHEMBL5563845 0.88 ACACB (0.37) ACACBACACAAAK1POLBTGFBR1
SCHEMBL5562906 0.86 POLB (0.37) AAK1POLBHDAC3HDAC1HDAC2
SCHEMBL5563152 0.85 SCN9A (0.39) ACACBACACAAAK1POLBTGFBR1
SCHEMBL5557333 0.84 AAK1 (0.42) AAK1POLBCYP3A4GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-B1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
US-6949542-B2 Dihydro-benzo[b][1,4]diazepin-2-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-09-27 US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 ACACB 2205/4885ACACA 2851/4885AAK1 2928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.